Press release from Companies
Publicerat: 2025-06-23 17:35:00
On 18 June 2024, the exercise period for warrants of series TO3, which were issued in connection with Curasight A/S (“Curasight” or the “Company”) rights issue and directed issue of units earlier in 2024 (“TO3”) ended. In total 3,501 warrants of series TO3 were exercised, corresponding to a subscription rate of approximately 0.19 percent. Curasight is thus provided approximately DKK 54,440.6 before deduction of transaction related costs.
Outcome of the exercise of warrants of series TO3
During the exercise period, 4-18 June 2025, holders of TO3 had the right to subscribe for one (1) new share in Curasight at a subscription price of DKK 15.55 per share. In total 3,501 warrants of series TO3 were exercised, corresponding to a subscription rate of approximately 0.19 percent. Curasight will thus receive approximately DKK 54,440.6 before deduction of transaction related costs.
Conversion from interim shares to ordinary shares is expected to take place around 2 July 2025.
Number of shares and share capital
The exercise of TO3 means that the number of shares in the Company increases by 3,501 shares and the share capital increases by DKK 175.05, resulting in a dilution effect of approximately 0.01 percent. When the new shares from TO3 have been registered with the Danish Business Authority, the total number of shares in Curasight will amount to 45,867,511 and the share capital will amount to DKK 2,293,375.55.
Advisors
Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
For more information regarding the warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
